Time to rethink the role of clinical pathways in the era of precision medicine: A lung cancer case study Editorial

  

Authors:	Schleicher, S. M.; Chaudhry, B.; Dickson, N. R.; Aviki, E.; Arrowsmith, E.; Parikh, R. B.; Yue, A. T.; Connor, N.; Schwartzberg, L.; Lyss, A. J.
Title:	Time to rethink the role of clinical pathways in the era of precision medicine: A lung cancer case study
Keywords:	unclassified drug; bevacizumab; gemcitabine; paclitaxel; cancer immunotherapy; lung cancer; editorial; cancer therapy; docetaxel; health care policy; health care quality; drug cost; health care cost; clinical pathway; drug utilization; pemetrexed; case study; personalized medicine; non small cell lung cancer; human; pembrolizumab; price; atezolizumab; atezolizumab plus bevacizumab plus paclitaxel; pembrolizumab plus pemetrexed
Journal Title:	JCO Oncology Practice
Volume:	17
Issue:	7
ISSN:	2688-1527
Publisher:	American Society of Clinical Oncology
Date Published:	2021-07-01
Start Page:	379
End Page:	381
Language:	English
DOI:	10.1200/op.21.00073
PUBMED:	33872069
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111108677&doi=10.1200%2fOP.21.00073&partnerID=40&md5=b2dd3ce339905f992f3a225f1cdf01ce
Notes:	Editorial -- Export Date: 1 September 2021 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/185987